Panel Discussion | The future of weight management: Navigating the Ozempic era

The GLP-1 revolution, led by drugs like Ozempic, Wegovy, and Munjaro is rapidly transforming the nutraceutical landscape. According to PwC research conducted in 2024, between 30% to 35% of Americans are interested in using GLP-1 medications, with current usage sitting at around a tenth of the US population. The immense changes in appetite, eating behaviours, and body composition brought about by these drugs offers significant challenges and opportunities for the supplement sector.

A critical concern is muscle loss during GLP-1 therapy, with studies suggesting 20-30% of weight loss may come from lean mass. This creates a demand for high-protein formulations, amino acid supplements, and creatine supplementation. Nutrient deficiencies due to reduced food intake present another opportunity for fortified products and targeted supplements.

Digital integration and AI-driven solutions could revolutionise supplement regimens and meal planning for GLP-1 users. Meanwhile, sensory neuroscience insights reveal how GLP-1s interact with brain-gut connections, opening doors for innovative product development. The GLP-1 revolution presents a unique moment for the nutraceutical industry to innovate and adapt. As the industry pivots, who will emerge as the frontrunners in this weight loss-driven market and who will be left behind?

Underwriting Partners: KERRY, TCI Biotech

By viewing this session, the sponsors may contact you with product and service information. You can unsubscribe or contact the sender anytime. See the Privacy Policy (https://privacy.informa.com/policies/en/) for details.